NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT
Phase 1/2Terminated 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Prostate Cancer
Conditions
Prostate Cancer
Trial Timeline
Nov 15, 2017 → Mar 19, 2020
NCT ID
NCT02805894About NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT
NBTXR3 activated by IMRT only + NBTXR3 activated by Brachytherapy & IMRT is a phase 1/2 stage product being developed by Nanobiotix for Prostate Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT02805894. Target conditions include Prostate Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02805894 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Prostate Cancer